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A recent article published in Brain proposes a clinical method for subtyping Parkinson disease 
cases on an individual basis, with implications for better patient stratification for personalized 
medicine. The authors report biological validity in terms of imaging and cerebrospinal fluid 
parameters, but long-term predictive validity remains to be established.  
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Parkinson disease (PD) is characterized by bradykinesia, tremor and rigidity linked to the core 
pathology of degeneration of dopaminergic neurons within the nigrostriatal system. However, it has 
long been recognized that patients with PD present and progress in different ways1. An ongoing 
challenge is to determine whether such distinctions really constitute disease subtypes and, if so, 
what is their underlying pathogenic basis? Fundamentally, this debate distils down to the question of 
whether PD exists in different pathogenic forms, or as one pathogenic form that runs with different 
kinetics in different patients. In a new paper, Seyed-Mohammad Fereshtehnejad and colleagues 
have added to the debate by using hierarchical cluster analysis of data collected from the 
Parkinson’s Progression Markers Initiative (PPMI) to define PD subtypes and explore their validity2. 
Cluster analysis is an unbiased approach that is driven by the data, and is not influenced by a priori 
hypotheses. This technique is not new, and it has been used in a number of studies in PD since the 
late 1990s3–5. Such studies have tended to agree that patients with PD can be grouped into three 
‘types’: a young-onset group with more tremor, a more benign course and fewer non-motor 
complications, consistent with predominant dopaminergic pathology; a group with more malignant, 
rapidly progressive disease consistent with widespread pathology, who are older at diagnosis; and 
an intermediate group. One of the key limitations of these studies is that they have described 
variability only at the group level. Translation of such findings to the individual patient level will be 
crucial to improve the stratification of patients for personalized medicine and clinical trials. 
Furthermore, little effort has been made to validate such subtyping at pathological and longitudinal 
levels. 
In their study2, Fereshtehnejad and colleagues have addressed some of these limitations, first, by 
using a cluster analysis of the PPMI cohort to define subtypes of disease that can be applied in 
individual patients and, second, by probing the neurobiological basis of these subtypes using 
comprehensive imaging and cerebrospinal fluid (CSF) data.  
The PPMI cohort comprises ‘de novo’ patients with PD recruited within 2 years of diagnosis and 
before commencing PD therapy. Hierarchical cluster analysis of baseline demographics, clinical 
(motor and non-motor) and neuropsychological data, and global genetic risk scores resulted in the 
definition of three distinct clusters of patients, which were broadly in keeping with the previous 
literature: a ‘mild motor-predominant’ group with younger onset, low motor Unified PD Rating Scale 
(UPDRS) scores and minimal non-motor features; a ‘diffuse malignant’ group with high motor and 
non-motor scores; and a third ‘intermediate’ group. Genetic risk scores did not contribute 
significantly to the clustering solution. 
The added value of this study derives from translation of these cluster analysis findings into a set of 
rules that allows stratification of every individual patient into one of the three specified groups 
(which is necessary because the nature of the cluster analysis approach means that not all patients 
will fall neatly into the statistically defined clusters). The methodology involved determining the key 
features that discriminated the clusters by means of principal component analysis, reducing these 
features into four composite domains (motor, cognition, REM sleep behaviour disorder and 
dysautonomia), and creating categorical definitions for subgroups, using the 75th percentile as a cut-
off to define low or high composite scores.  
The authors demonstrated the validity of the three defined clinical subtypes in terms of both 
imaging biomarkers (MRI morphometry data showed that atrophy in a PD-specific brain network 
was most severe in the ‘diffuse malignant’ group and least severe in the ‘mild motor-predominant’ 
group) and CSF biomarkers (lowest amyloid-β (Aβ) levels and Aβ:tau ratio in the ‘diffuse malignant’ 
group). Furthermore, they demonstrated that these subtypes have longitudinal validity — albeit 
over a short follow-up duration (average 2.7 years) — with the ‘diffuse malignant’ group exhibiting 
the fastest global progression, the greatest cognitive decline on the Montreal Cognitive Assessment, 
and the most rapid decline in tracer uptake on dopamine transporter single-photon emission CT. 
Major strengths of the study include the de novo nature of the cohort (thus avoiding the 
confounding effect of disease stage), and the availability of such comprehensive data, including 
imaging and biomarker data, allowing investigation of the biological validity of the subtypes. 
However, an important caveat is that the outcome of any cluster analysis depends on the variables 
selected for inclusion — a point that is well illustrated by the differing results produced by Erro et al. 
in a cluster analysis that used the same PPMI data6. Erro et al. identified apathy and hallucinations as 
key subtype classifiers, but these variables were not included by the current authors, as they were 
only measured by one item on the UPDRS. Furthermore, as Fereshtehnejad et al. acknowledge2, the 
PPMI cohort is not population-representative, but biased towards individuals with higher education, 
greater motivation and younger age (mean 61.1 years, compared with 72.0 years in population-
representative cohorts)7. It is unclear whether the under-represented patients would fit into the 
three-subtype solution, or whether they represent another distinct subtype (possibly an older group 
with relatively mild, benign disease, which is anecdotally recognizable in clinical practice). 
The new study also failed to find evidence for genetic heterogeneity in association with the observed 
clinical heterogeneity2, which is somewhat at odds with the existing literature. In particular, an 
association between GBA mutations and more-rapid motor disease progression is well described, as 
are associations between GBA, MAPT and APOE*ε4 and cognitive decline8. This discrepancy might be 
explained by the fact that the genetic risk score employed in this study was derived from 28 variants 
associated with disease risk, which could dilute the impact of variation at any individual loci. In 
addition, genetic variants that underlie clinical heterogeneity might differ from those that underlie 
disease risk. 
Despite these limitations, this study has added weight to the concept of PD subtypes. It has 
considerable value in providing a practical method (available as an Excel calculator) for subtyping of 
patients on an individual basis, and in demonstrating that these subtypes differ biologically and 
longitudinally. The predictive validity of this new framework now needs to be tested over longer 
follow-up periods, ideally in independent population-representative cohorts. Recently, the first 
predictive models for use in individual patients, based on a few simple baseline parameters, were 
developed. Velsboer et al. developed an algorithm predicting 5-year outcome (dementia, postural 
instability or death) on the basis of age, UPDRS axial score and semantic fluency9, whereas Scherzer 
et al. developed an algorithm predicting 10-year dementia risk using GBA genotype, age, Mini-
Mental State Examination score, education, UPDRS motor score, gender, and depression10. Both 
models were shown to have an accuracy of 85%. 
The next challenge will be to determine the minimal data set needed to facilitate disease subtyping 
with the necessary fidelity for translation to the clinic, with the aim of achieving more-personalized 
treatments and prognoses, as well as better-stratified clinical trials. 
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